




- ➔ 12 Recession Beaters For 2008
- ➔ What \$1 Million Buys in Homes With
- ➔ Most Overpriced Vehicles



Search: **Forbes.com** Quotes Video Web Blogs Advanced

Go



U.S. EUROPE ASIA HOME PAGE FOR THE WORLD'S BUSINESS LEADERS Free Trial Issue

HOME BUSINESS TECH MARKETS ENTREPRENEURS LEADERSHIP PERSONAL FINANCE FORBESLI

Video Blogs E-mail Newsletters Org Chart Wiki People Tracker Portfolio Tracker Special Reports Widgets

E-mail | Request Reprints | E-Mail Newsletters | My Yahoo! | RSS

ADVERTISEMENT

Business Wire - Press Release



Yissum and Eucalyptus Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

01.08.08, 7:02 AM ET

Most Popular Stories

- [The Biggest Celebrity Paydays Of 2007](#)
- [America's Most Lustful Cities](#)
- [Worst States for Speeding](#)
- [The NFL's Coldest Games](#)
- [How to Choose Gifts to Re-Gift or Resell](#)

Popular Videos

- [Queen Of YouTube](#)
- [Boxing's Best](#)
- [Leno & Letterman Strike Back](#)
- [Politics: A National Primary?](#)
- [Gold, Oil and the Dollar](#)

Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, today announced that it has licensed an orally-available small molecule for several biological indications including the treatment of neurodegenerative diseases to Eucalyptus Ltd. The molecule is an antioxidant that overcomes the blood-brain barrier.

"This invention, by Professor Daphne Atlas, jointly developed with Dr. Daniel Offen and Professor Eldad Melamed, is a breakthrough in the treatment of oxidative stress, which plays a major role in CNS disorders," stated Nava Swersky Sofer, CEO of Yissum. "We are delighted to collaborate with Professor Ashley Bush, CSO, Eucalyptus, a leading expert in Alzheimer's research to take our invention into the clinic for the benefit of patients."

Under the terms of the agreement, Eucalyptus has acquired worldwide exclusive rights to develop and commercialize the molecule and Yissum together with Ramot, the technology transfer company of Tel Aviv University, and Mor Research Applications, the technology transfer company of Clalit Health Services, will receive upfront payments, milestone payments in accordance with development progress and royalties from sales of final products.

Attract the brightest project management stars.

PMI is a registered trademark of the Project M

[Make Forbes.com My Home Page](#)

Trading Center

Brought to y



[ForbesAutos.com](#)

The molecule, N-acetylcysteine amide (AD4), is an antioxidant for the prevention and treatment of Parkinson's, Alzheimer's, multiple sclerosis and other neurodegenerative diseases that are linked to oxidative stress, and also has broader applications in biology. Oxidative stress, induced by free radicals, plays an important role in the progression of neurodegenerative and age-related diseases, causing damage to proteins, DNA, and lipids. For example, increasing evidence correlates Parkinson's disease with the accumulation of oxidative damage in specific neurons in the brain. AD4 is administered orally, and is able to cross the blood-brain barrier, thus overcoming a major obstacle of central nervous system (CNS) directed drugs.

Pre-clinical data showed the ability of AD4 to protect cells in culture from oxidative damage. Furthermore, the molecule was shown to protect neuronal cells from damage in rodent models of both Parkinson's disease and multiple sclerosis. The low toxicity of AD4, as evidenced in the lab, together with its neuroprotective function and high bioavailability make it highly suitable for the treatment of CNS disorders.

The molecule was invented by Daphne Atlas, Ph.D., Professor of Neurochemistry at the Hebrew University of Jerusalem, Israel. The work was performed in collaboration with Dr. Daniel Offen, Ph.D. from the Tel Aviv University, Israel and Eldad Melamed, MD, Professor and Chairman of the Department of Neurology at the Rabin Medical Center, Petah Tiqva, Israel.

"In our aging society, in which neurodegenerative diseases have become more common, there is a growing need for safe and effective drugs for age-related diseases. AD4 which overcomes the blood-brain barrier, is an excellent candidate for both the prevention and treatment of various neurodegenerative disorders," commented Prof. Daphne Atlas.

Professor Ashley Bush, CSO, Eucalyptus, added "We are excited to be able to progress the pioneering work of our Israeli collaborators towards commercialization. I am very confident that AD4 will be therapeutically useful for several major neurological disorders, certain major psychiatric conditions as well as several other biological applications. I expect this to be a rapid development project."

About Yissum

Yissum was founded in 1964 to protect the Hebrew University's intellectual property and commercialise it. \$1 Billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 5000 patents covering 1400 inventions; licensed out 400 technologies and spun out 60 companies. Yissum's business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more. For further information please visit www.yissum.co.il.


1 of 1

Article Controls

[E-mail](#) | [Request Reprints](#) | [E-Mail Newsletters](#) | [My Yahoo!](#) | [RSS](#)

Related Sections

[Home > News & Analysis](#)



Small Business




The Entrepreneur

Ten books that no should be without

Sponsored By


CEO Book Club



Zugzwang

David A.andelman
In Russia, at times che murder.


[READ REVIEW](#)



The Sound Of Silence

Paul Maudit
Having trouble managi
Maybe you talk too mu

[READ REVIEW](#)



[News Headlines](#) | [More From Forbes.com](#) | [Special Reports](#)

Subscriptions >

[Subscribe To Newsletters](#) [Subscriber Customer Service](#)

More From **Forbes** COM

- [➔ America's Hot Companies](#)
- [➔ Most Dangerous Cities for Driving in the U.S.](#)
- [➔ The Web Celeb 25](#)
- [➔ America's Most Lustful Cities](#)
- [➔ Nine International Buys for 2008](#)

[SITEMAP](#) [HELP](#) [CONTACT US](#) [INVESTMENT NEWSLETTERS](#) [FORBES CONFERENCES](#) [FORBES MAGAZINES](#)

[Ad Information](#) [Forbes.com Mobile](#) [RSS](#) [Reprints/Permissions](#) [Subscriber Services](#)
© 2008 Forbes.com LLC™ All Rights Reserved [Privacy Statement](#) [Terms, Conditions and N](#)

Tested By	Market Data By	Market Data By	Market Data By	Investopedia	Polska	Luxury Cars

Stock quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for NYSE/AMEX.U.S. indexes are delayed at least 15 minutes with the exception of Nasdaq, Dow Jones Industrial Average and S&P 500 which are 2 minutes delayed.

Powered By	Oracle DBA by
Intelligent Content Distribution System	REMOTE DBA Oracle • SQL • MySQL

